Compare Citius Pharmaceuticals Inc (CTXR) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs ING Groep NV — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while ING Groep NV trades at $33.28 (market cap $96.81B). The key difference: ING Groep NV is far larger — about 7020.3× Citius Pharmaceuticals Inc's market cap, and ING Groep NV pays a 3.9% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and ING Groep NV for 93 Days on average.
| CTXR | ING | |
|---|---|---|
Market Cap | $13.79M | $96.81B |
Volume | 156,684 | 2,635,505 |
Sector | Health | Financials |
52-Week High | $1.82 | $37.27 |
52-Week Low | $0.48 | $23.66 |
Typical Hold Time | 16 Days | 93 Days |
Enterprise Value | $3.96M | $236.31B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
ING stock trades at $33.43, down 4.21% with bearish technical signals despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters with Q2 2026 EPS of $0.79 versus $0.75 expected. Revenue growth remains steady at $22.9B in 2025 with a robust 28.34% net margin. Analyst consensus is strongly bullish with 11 buy ratings and no sell recommendations.
The stock presents a value opportunity with a reasonable P/E of 13.09 and strong profitability metrics, though negative cash flow trends and regulatory challenges in Australia warrant monitoring. Management's raised ROE target above 16% for 2027 signals confidence in continued operational improvement and strategic execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
